Arix Bioscience portfolio company VelosBio closes $137m Series B
Read more on VelosBio in this latest blog post by Arix Managing Director and VelosBio Board Director Jonathan Tobin
Read more on VelosBio in this latest blog post by Arix Managing Director and VelosBio Board Director Jonathan Tobin
European investors continue actively investing in healthcare. The survey held in May 2020 includes responses from 24 of the most influential European VCs, investing approximately EUR 15.5 billion in aggregate in the Healthcare sector.
“A viable therapeutic would dramatically change the tone of the COVID-19 pandemic, giving hope and a path to eradicating the virus, saving lives and livelihoods.”
Insightful interview into the work of Entrepeneur In Residence, Dr Christian Schetter of Arix Bioscience
Arix Bioscience (ARIX) CEO Joe Anderson talked to VoxMarkets about investing in and building breakthrough biotech companies to market.